Loading…
Direct and rapid inhibition of factor Xa by otamixaban: A pharmacokinetic and pharmacodynamic investigation in patients with coronary artery disease
Background New anticoagulants that combine effective anticoagulation with low bleeding rates are still sought after. We investigated the safety, pharmacokinetics, and pharmacodynamics of otamixaban, a direct factor Xa inhibitor, in patients with stable coronary artery disease. Methods This was a ran...
Saved in:
| Published in: | Clinical pharmacology and therapeutics 2006-12, Vol.80 (6), p.691-702 |
|---|---|
| Main Authors: | , , , , , , |
| Format: | Article |
| Language: | English |
| Subjects: | |
| Citations: | Items that cite this one |
| Online Access: | Get full text |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| cited_by | cdi_FETCH-LOGICAL-c3015-ed3fdb39b3a81af3e0b4f01a1f8f6d27c97326d936d1b0580c84712d09cd4f143 |
|---|---|
| cites | |
| container_end_page | 702 |
| container_issue | 6 |
| container_start_page | 691 |
| container_title | Clinical pharmacology and therapeutics |
| container_volume | 80 |
| creator | Hinder, Markus Frick, Annke Jordaan, Pierre Hesse, Galina Gebauer, Alexander Maas, Jochen Paccaly, Anne |
| description | Background
New anticoagulants that combine effective anticoagulation with low bleeding rates are still sought after. We investigated the safety, pharmacokinetics, and pharmacodynamics of otamixaban, a direct factor Xa inhibitor, in patients with stable coronary artery disease.
Methods
This was a randomized, placebo‐controlled, double‐blind, multicenter study in 119 patients with stable coronary artery disease taking maintenance doses of their comedication. Of these patients, 50% had mild renal impairment (creatinine clearance >45 mL/min but |
| doi_str_mv | 10.1016/j.clpt.2006.09.002 |
| format | article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_68255158</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>68255158</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3015-ed3fdb39b3a81af3e0b4f01a1f8f6d27c97326d936d1b0580c84712d09cd4f143</originalsourceid><addsrcrecordid>eNqNksmOEzEQhi0EYjIDL8AB-QK3brz04uaANArDIkViDkHiZlV7IQ4du7EdhrwHD4wzCZorpyqXvvqrVL8RekFJTQnt3mxrNc25ZoR0NRlqQtgjtKAtZ1XX8vYxWhBChmpgvLtAlylty7MZhHiKLmhPe8G6YYH-vHfRqIzBaxxhdho7v3Gjyy54HCy2oHKI-Bvg8YBDhp37DSP4t_gazxuIO1Dhh_MmO3Uv8a-mD76gqoj9Mim773Cv5zyeS2Z8TvjO5Q1WIQYP8YAhZlOCdslAMs_QEwtTMs_P8Qp9_XCzXn6qVl8-fl5eryrFCW0ro7nVIx9GDoKC5YaMjSUUqBW206xXQ89ZpwfeaTqSVhAlmp4yTQalG0sbfoVen3TnGH7uy6Jy55Iy0wTehH2SnWBtS1tRQHYCVQwpRWPlHN2uLC4pkUcv5FYevZBHLyQZZPGiNL08q-_HndEPLefjF-DVGYCkYLIRvHLpgRMNET3pCvfuxN25yRz-Y7Rc3q6Xq9v1sdSUv_AXoT-pwg</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>68255158</pqid></control><display><type>article</type><title>Direct and rapid inhibition of factor Xa by otamixaban: A pharmacokinetic and pharmacodynamic investigation in patients with coronary artery disease</title><source>Wiley-Blackwell Read & Publish Collection</source><creator>Hinder, Markus ; Frick, Annke ; Jordaan, Pierre ; Hesse, Galina ; Gebauer, Alexander ; Maas, Jochen ; Paccaly, Anne</creator><creatorcontrib>Hinder, Markus ; Frick, Annke ; Jordaan, Pierre ; Hesse, Galina ; Gebauer, Alexander ; Maas, Jochen ; Paccaly, Anne</creatorcontrib><description>Background
New anticoagulants that combine effective anticoagulation with low bleeding rates are still sought after. We investigated the safety, pharmacokinetics, and pharmacodynamics of otamixaban, a direct factor Xa inhibitor, in patients with stable coronary artery disease.
Methods
This was a randomized, placebo‐controlled, double‐blind, multicenter study in 119 patients with stable coronary artery disease taking maintenance doses of their comedication. Of these patients, 50% had mild renal impairment (creatinine clearance >45 mL/min but <80 mL/min). Patients were randomized in a 4:1 ratio to receive either otamixaban or placebo as a 1‐minute bolus followed by a 24‐hour continuous infusion. Anti–factor Xa activity, clotting times (activated partial thromboplastin time, dilute prothrombin time, Russell's viper venom test), and international normalized ratio were measured.
Results
All patients completed the study according to the protocol. No major or minor bleeding occurred according to Thrombosis in Myocardial Infarction criteria. Anti–factor Xa activity and anticoagulant effect were measurable early after the start of the infusion and remained during the infusion. Upon cessation, these effects declined rapidly and returned to baseline within 6 hours after the end of infusion. Anti–factor Xa activity coincided with the otamixaban plasma concentrations. The fold changes from baseline at the end of infusion with regard to the clotting times ranged from 1.7 to 4.4 (1.15 for placebo), 1.29 to 3.15 (0.98 for placebo), and 1.19 to 2.11 (0.94 for placebo) for Russell's viper venom test, dilute prothrombin time, and activated partial thromboplastin time, respectively, and ranged from 0.94 to 1.70 (0.94 for placebo) for the international normalized ratio.
Conclusion
In patients with stable coronary artery disease taking maintenance doses of their usual concomitant medication, otamixaban exerts a rapid onset of anticoagulation and anti–factor Xa activity. Our data provide evidence that further studies are warranted to investigate the safety and efficacy of otamixaban in the target population.
Clinical Pharmacology & Therapeutics (2006) 80, 691–702; doi: 10.1016/j.clpt.2006.09.002</description><identifier>ISSN: 0009-9236</identifier><identifier>EISSN: 1532-6535</identifier><identifier>DOI: 10.1016/j.clpt.2006.09.002</identifier><identifier>PMID: 17178269</identifier><identifier>CODEN: CLPTAT</identifier><language>eng</language><publisher>New York, NY: Nature Publishing</publisher><subject>Adult ; Aged ; Area Under Curve ; Biological and medical sciences ; Cardiology. Vascular system ; Comorbidity ; Coronary Disease - drug therapy ; Coronary Disease - metabolism ; Coronary heart disease ; Cyclic N-Oxides - pharmacokinetics ; Cyclic N-Oxides - pharmacology ; Cyclic N-Oxides - therapeutic use ; Double-Blind Method ; Factor Xa Inhibitors ; Female ; Heart ; Humans ; Infusions, Intravenous ; International Normalized Ratio ; Male ; Medical sciences ; Metabolic Clearance Rate ; Middle Aged ; Pharmacology. Drug treatments ; Pyridines - pharmacokinetics ; Pyridines - pharmacology ; Pyridines - therapeutic use</subject><ispartof>Clinical pharmacology and therapeutics, 2006-12, Vol.80 (6), p.691-702</ispartof><rights>2006 American Society for Clinical Pharmacology and Therapeutics</rights><rights>2007 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c3015-ed3fdb39b3a81af3e0b4f01a1f8f6d27c97326d936d1b0580c84712d09cd4f143</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27901,27902</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=18408706$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/17178269$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Hinder, Markus</creatorcontrib><creatorcontrib>Frick, Annke</creatorcontrib><creatorcontrib>Jordaan, Pierre</creatorcontrib><creatorcontrib>Hesse, Galina</creatorcontrib><creatorcontrib>Gebauer, Alexander</creatorcontrib><creatorcontrib>Maas, Jochen</creatorcontrib><creatorcontrib>Paccaly, Anne</creatorcontrib><title>Direct and rapid inhibition of factor Xa by otamixaban: A pharmacokinetic and pharmacodynamic investigation in patients with coronary artery disease</title><title>Clinical pharmacology and therapeutics</title><addtitle>Clin Pharmacol Ther</addtitle><description>Background
New anticoagulants that combine effective anticoagulation with low bleeding rates are still sought after. We investigated the safety, pharmacokinetics, and pharmacodynamics of otamixaban, a direct factor Xa inhibitor, in patients with stable coronary artery disease.
Methods
This was a randomized, placebo‐controlled, double‐blind, multicenter study in 119 patients with stable coronary artery disease taking maintenance doses of their comedication. Of these patients, 50% had mild renal impairment (creatinine clearance >45 mL/min but <80 mL/min). Patients were randomized in a 4:1 ratio to receive either otamixaban or placebo as a 1‐minute bolus followed by a 24‐hour continuous infusion. Anti–factor Xa activity, clotting times (activated partial thromboplastin time, dilute prothrombin time, Russell's viper venom test), and international normalized ratio were measured.
Results
All patients completed the study according to the protocol. No major or minor bleeding occurred according to Thrombosis in Myocardial Infarction criteria. Anti–factor Xa activity and anticoagulant effect were measurable early after the start of the infusion and remained during the infusion. Upon cessation, these effects declined rapidly and returned to baseline within 6 hours after the end of infusion. Anti–factor Xa activity coincided with the otamixaban plasma concentrations. The fold changes from baseline at the end of infusion with regard to the clotting times ranged from 1.7 to 4.4 (1.15 for placebo), 1.29 to 3.15 (0.98 for placebo), and 1.19 to 2.11 (0.94 for placebo) for Russell's viper venom test, dilute prothrombin time, and activated partial thromboplastin time, respectively, and ranged from 0.94 to 1.70 (0.94 for placebo) for the international normalized ratio.
Conclusion
In patients with stable coronary artery disease taking maintenance doses of their usual concomitant medication, otamixaban exerts a rapid onset of anticoagulation and anti–factor Xa activity. Our data provide evidence that further studies are warranted to investigate the safety and efficacy of otamixaban in the target population.
Clinical Pharmacology & Therapeutics (2006) 80, 691–702; doi: 10.1016/j.clpt.2006.09.002</description><subject>Adult</subject><subject>Aged</subject><subject>Area Under Curve</subject><subject>Biological and medical sciences</subject><subject>Cardiology. Vascular system</subject><subject>Comorbidity</subject><subject>Coronary Disease - drug therapy</subject><subject>Coronary Disease - metabolism</subject><subject>Coronary heart disease</subject><subject>Cyclic N-Oxides - pharmacokinetics</subject><subject>Cyclic N-Oxides - pharmacology</subject><subject>Cyclic N-Oxides - therapeutic use</subject><subject>Double-Blind Method</subject><subject>Factor Xa Inhibitors</subject><subject>Female</subject><subject>Heart</subject><subject>Humans</subject><subject>Infusions, Intravenous</subject><subject>International Normalized Ratio</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Metabolic Clearance Rate</subject><subject>Middle Aged</subject><subject>Pharmacology. Drug treatments</subject><subject>Pyridines - pharmacokinetics</subject><subject>Pyridines - pharmacology</subject><subject>Pyridines - therapeutic use</subject><issn>0009-9236</issn><issn>1532-6535</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2006</creationdate><recordtype>article</recordtype><recordid>eNqNksmOEzEQhi0EYjIDL8AB-QK3brz04uaANArDIkViDkHiZlV7IQ4du7EdhrwHD4wzCZorpyqXvvqrVL8RekFJTQnt3mxrNc25ZoR0NRlqQtgjtKAtZ1XX8vYxWhBChmpgvLtAlylty7MZhHiKLmhPe8G6YYH-vHfRqIzBaxxhdho7v3Gjyy54HCy2oHKI-Bvg8YBDhp37DSP4t_gazxuIO1Dhh_MmO3Uv8a-mD76gqoj9Mim773Cv5zyeS2Z8TvjO5Q1WIQYP8YAhZlOCdslAMs_QEwtTMs_P8Qp9_XCzXn6qVl8-fl5eryrFCW0ro7nVIx9GDoKC5YaMjSUUqBW206xXQ89ZpwfeaTqSVhAlmp4yTQalG0sbfoVen3TnGH7uy6Jy55Iy0wTehH2SnWBtS1tRQHYCVQwpRWPlHN2uLC4pkUcv5FYevZBHLyQZZPGiNL08q-_HndEPLefjF-DVGYCkYLIRvHLpgRMNET3pCvfuxN25yRz-Y7Rc3q6Xq9v1sdSUv_AXoT-pwg</recordid><startdate>200612</startdate><enddate>200612</enddate><creator>Hinder, Markus</creator><creator>Frick, Annke</creator><creator>Jordaan, Pierre</creator><creator>Hesse, Galina</creator><creator>Gebauer, Alexander</creator><creator>Maas, Jochen</creator><creator>Paccaly, Anne</creator><general>Nature Publishing</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>200612</creationdate><title>Direct and rapid inhibition of factor Xa by otamixaban: A pharmacokinetic and pharmacodynamic investigation in patients with coronary artery disease</title><author>Hinder, Markus ; Frick, Annke ; Jordaan, Pierre ; Hesse, Galina ; Gebauer, Alexander ; Maas, Jochen ; Paccaly, Anne</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3015-ed3fdb39b3a81af3e0b4f01a1f8f6d27c97326d936d1b0580c84712d09cd4f143</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2006</creationdate><topic>Adult</topic><topic>Aged</topic><topic>Area Under Curve</topic><topic>Biological and medical sciences</topic><topic>Cardiology. Vascular system</topic><topic>Comorbidity</topic><topic>Coronary Disease - drug therapy</topic><topic>Coronary Disease - metabolism</topic><topic>Coronary heart disease</topic><topic>Cyclic N-Oxides - pharmacokinetics</topic><topic>Cyclic N-Oxides - pharmacology</topic><topic>Cyclic N-Oxides - therapeutic use</topic><topic>Double-Blind Method</topic><topic>Factor Xa Inhibitors</topic><topic>Female</topic><topic>Heart</topic><topic>Humans</topic><topic>Infusions, Intravenous</topic><topic>International Normalized Ratio</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Metabolic Clearance Rate</topic><topic>Middle Aged</topic><topic>Pharmacology. Drug treatments</topic><topic>Pyridines - pharmacokinetics</topic><topic>Pyridines - pharmacology</topic><topic>Pyridines - therapeutic use</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Hinder, Markus</creatorcontrib><creatorcontrib>Frick, Annke</creatorcontrib><creatorcontrib>Jordaan, Pierre</creatorcontrib><creatorcontrib>Hesse, Galina</creatorcontrib><creatorcontrib>Gebauer, Alexander</creatorcontrib><creatorcontrib>Maas, Jochen</creatorcontrib><creatorcontrib>Paccaly, Anne</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Clinical pharmacology and therapeutics</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Hinder, Markus</au><au>Frick, Annke</au><au>Jordaan, Pierre</au><au>Hesse, Galina</au><au>Gebauer, Alexander</au><au>Maas, Jochen</au><au>Paccaly, Anne</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Direct and rapid inhibition of factor Xa by otamixaban: A pharmacokinetic and pharmacodynamic investigation in patients with coronary artery disease</atitle><jtitle>Clinical pharmacology and therapeutics</jtitle><addtitle>Clin Pharmacol Ther</addtitle><date>2006-12</date><risdate>2006</risdate><volume>80</volume><issue>6</issue><spage>691</spage><epage>702</epage><pages>691-702</pages><issn>0009-9236</issn><eissn>1532-6535</eissn><coden>CLPTAT</coden><abstract>Background
New anticoagulants that combine effective anticoagulation with low bleeding rates are still sought after. We investigated the safety, pharmacokinetics, and pharmacodynamics of otamixaban, a direct factor Xa inhibitor, in patients with stable coronary artery disease.
Methods
This was a randomized, placebo‐controlled, double‐blind, multicenter study in 119 patients with stable coronary artery disease taking maintenance doses of their comedication. Of these patients, 50% had mild renal impairment (creatinine clearance >45 mL/min but <80 mL/min). Patients were randomized in a 4:1 ratio to receive either otamixaban or placebo as a 1‐minute bolus followed by a 24‐hour continuous infusion. Anti–factor Xa activity, clotting times (activated partial thromboplastin time, dilute prothrombin time, Russell's viper venom test), and international normalized ratio were measured.
Results
All patients completed the study according to the protocol. No major or minor bleeding occurred according to Thrombosis in Myocardial Infarction criteria. Anti–factor Xa activity and anticoagulant effect were measurable early after the start of the infusion and remained during the infusion. Upon cessation, these effects declined rapidly and returned to baseline within 6 hours after the end of infusion. Anti–factor Xa activity coincided with the otamixaban plasma concentrations. The fold changes from baseline at the end of infusion with regard to the clotting times ranged from 1.7 to 4.4 (1.15 for placebo), 1.29 to 3.15 (0.98 for placebo), and 1.19 to 2.11 (0.94 for placebo) for Russell's viper venom test, dilute prothrombin time, and activated partial thromboplastin time, respectively, and ranged from 0.94 to 1.70 (0.94 for placebo) for the international normalized ratio.
Conclusion
In patients with stable coronary artery disease taking maintenance doses of their usual concomitant medication, otamixaban exerts a rapid onset of anticoagulation and anti–factor Xa activity. Our data provide evidence that further studies are warranted to investigate the safety and efficacy of otamixaban in the target population.
Clinical Pharmacology & Therapeutics (2006) 80, 691–702; doi: 10.1016/j.clpt.2006.09.002</abstract><cop>New York, NY</cop><pub>Nature Publishing</pub><pmid>17178269</pmid><doi>10.1016/j.clpt.2006.09.002</doi><tpages>12</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0009-9236 |
| ispartof | Clinical pharmacology and therapeutics, 2006-12, Vol.80 (6), p.691-702 |
| issn | 0009-9236 1532-6535 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_68255158 |
| source | Wiley-Blackwell Read & Publish Collection |
| subjects | Adult Aged Area Under Curve Biological and medical sciences Cardiology. Vascular system Comorbidity Coronary Disease - drug therapy Coronary Disease - metabolism Coronary heart disease Cyclic N-Oxides - pharmacokinetics Cyclic N-Oxides - pharmacology Cyclic N-Oxides - therapeutic use Double-Blind Method Factor Xa Inhibitors Female Heart Humans Infusions, Intravenous International Normalized Ratio Male Medical sciences Metabolic Clearance Rate Middle Aged Pharmacology. Drug treatments Pyridines - pharmacokinetics Pyridines - pharmacology Pyridines - therapeutic use |
| title | Direct and rapid inhibition of factor Xa by otamixaban: A pharmacokinetic and pharmacodynamic investigation in patients with coronary artery disease |
| url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-05T23%3A53%3A53IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Direct%20and%20rapid%20inhibition%20of%20factor%20Xa%20by%20otamixaban:%20A%20pharmacokinetic%20and%20pharmacodynamic%20investigation%20in%20patients%20with%20coronary%20artery%20disease&rft.jtitle=Clinical%20pharmacology%20and%20therapeutics&rft.au=Hinder,%20Markus&rft.date=2006-12&rft.volume=80&rft.issue=6&rft.spage=691&rft.epage=702&rft.pages=691-702&rft.issn=0009-9236&rft.eissn=1532-6535&rft.coden=CLPTAT&rft_id=info:doi/10.1016/j.clpt.2006.09.002&rft_dat=%3Cproquest_cross%3E68255158%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c3015-ed3fdb39b3a81af3e0b4f01a1f8f6d27c97326d936d1b0580c84712d09cd4f143%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=68255158&rft_id=info:pmid/17178269&rfr_iscdi=true |